← All trials
NCT05730283
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2023
- Primary completion
- Jan 1, 2027
- Completion date
- Jan 1, 2027
- First posted
- Feb 15, 2023
- Last posted
- Feb 15, 2023
- Enrollment
- 105
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Oregon Health and Science UniversityLead sponsor
- Mayo ClinicCollaborator
- Medical University of South CarolinaCollaborator
- National Center for Advancing Translational Science (NCATS)Collaborator
- National Institute on Deafness and Other Communication Disorders (NIDCD)Collaborator
- University of Colorado, DenverCollaborator
- Oregon Health and Science UniversityOverall official - principal investigator
- Oregon Health and Science UniversitySponsor investigator
- University of Texas, TylerCollaborator
- University of WashingtonCollaborator
- Oregon Health and Science UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.